Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Jazz Pharmaceuticals PLC (JAZZ : NSDQ)

• Company Description    Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'. Number of Employees: 2,890

• Price / Volume Information    Yesterday's Closing Price: $253.87 Daily Weekly Monthly 20 Day Moving Average: 697,029 shares Shares Outstanding: 62.82 (millions) Market Capitalization: $15,947.51 (millions) Beta: 0.32 52 Week High: $256.75 52 Week Low: $105.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 10.37% 9.51% 12 Week 25.23% 22.16% Year To Date 49.33% 37.92%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD - DUBLIN,L2 D04 E5W7 IRL ph: 011-353-1634-7800 fax: 353-1634-7850 investorinfo@jazzpharma.com http://www.jazzpharma.com

• General Corporate Information    Officers Renee D. Gala - Chief Executive Officer; President and Director Bruce C. Cozadd - Chairman Philip L. Johnson - Executive Vice President and Chief Financial Offic Jennifer E. Cook - Director Patrick G. Enright - Director Peer Information Jazz Pharmaceuticals PLC (CORR.) Jazz Pharmaceuticals PLC (RSPI) Jazz Pharmaceuticals PLC (CGXP) Jazz Pharmaceuticals PLC (BGEN) Jazz Pharmaceuticals PLC (GTBP) Jazz Pharmaceuticals PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G50871105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/03/26 Share - Related Items Shares Outstanding: 62.82 Most Recent Split Date: (:1) Beta: 0.32 Market Capitalization: $15,947.51 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $5.38 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $21.90 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 51.76% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/26

• Fundamental Ratios P/E Current FY Estimate: 11.59 Trailing 12 Months: 27.78 PEG Ratio: 0.22 Price Ratios Price/Book: 3.51 Price/Cash Flow: 15.61 Price / Sales: 3.59 EPS Growth vs. Year Ago Period: 810.00% vs. Previous Quarter: -5.21% Sales Growth vs. Year Ago Period: 19.05% vs. Previous Quarter: -10.77% ROE 06/30/26 - - 03/31/26 - 14.56 12/31/25 - 6.87 ROA 06/30/26 - - 03/31/26 - 5.25 12/31/25 - 2.44 Current Ratio 06/30/26 - - 03/31/26 - 2.04 12/31/25 - 1.86 Quick Ratio 06/30/26 - - 03/31/26 - 1.85 12/31/25 - 1.67 Operating Margin 06/30/26 - - 03/31/26 - 13.55 12/31/25 - 6.51 Net Margin 06/30/26 - - 03/31/26 - 0.66 12/31/25 - -8.35 Pre-Tax Margin 06/30/26 - - 03/31/26 - -4.93 12/31/25 - -14.71 Book Value 06/30/26 - - 03/31/26 - 72.24 12/31/25 - 71.07 Inventory Turnover 06/30/26 - - 03/31/26 - 1.16 12/31/25 - 1.06 Debt-to-Equity 06/30/26 - - 03/31/26 - 0.95 12/31/25 - 1.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 48.83 12/31/25 - 50.06

Powered by Zacks Investment Research ©